|Classification and external resources|
|ICD-10||H36 (E10.3 E11.3 E12.3 E13.3 E14.3)|
It is an ocular manifestation of diabetes, a systemic disease, which affects up to 80 percent of all patients who have had diabetes for 10 years or more. Despite these intimidating statistics, research indicates that at least 90% of these new cases could be reduced if there were proper and vigilant treatment and monitoring of the eyes. The longer a person has diabetes, the higher his or her chances of developing diabetic retinopathy. Each year in the United States, diabetic retinopathy accounts for 12% of all new cases of blindness. It is also the leading cause of blindness for people aged 20 to 64 years.
- 1 Signs and symptoms
- 2 Risk factors
- 3 Pathogenesis
- 4 Diagnosis
- 5 Management
- 6 Research
- 7 See also
- 8 References
- 9 External links
Signs and symptoms
Diabetic retinopathy often has no early warning signs. Even macular edema, which can cause rapid vision loss, may not have any warning signs for some time. In general, however, a person with macular edema is likely to have blurred vision, making it hard to do things like read or drive. In some cases, the vision will get better or worse during the day.
In the first stage which is called non-proliferative diabetic retinopathy (NPDR) there are no symptoms, the signs are not visible to the eye and patients will have 20/20 vision. The only way to detect NPDR is by fundus photography, in which microaneurysms (microscopic blood-filled bulges in the artery walls) can be seen. If there is reduced vision, fluorescein angiography can be done to see the back of the eye. Narrowing or blocked retinal blood vessels can be seen clearly and this is called retinal ischemia (lack of blood flow).
Macular edema in which blood vessels leak their contents into the macular region can occur at any stage of NPDR. The symptoms of macular edema are blurred vision and darkened or distorted images that are not the same in both eyes. Ten percent (10%) of diabetic patients will have vision loss related to macular edema. Optical Coherence Tomography can show the areas of retinal thickening (due to fluid accumulation) of macular edema.
In the second stage, abnormal new blood vessels (neovascularisation) form at the back of the eye as part of proliferative diabetic retinopathy (PDR); these can burst and bleed (vitreous hemorrhage) and blur the vision, because these new blood vessels are fragile. The first time this bleeding occurs, it may not be very severe. In most cases, it will leave just a few specks of blood, or spots floating in a person's visual field, though the spots often go away after a few hours.
These spots are often followed within a few days or weeks by a much greater leakage of blood, which blurs the vision. In extreme cases, a person may only be able to tell light from dark in that eye. It may take the blood anywhere from a few days to months or even years to clear from the inside of the eye, and in some cases the blood will not clear. These types of large hemorrhages tend to happen more than once, often during sleep.
All people with diabetes mellitus are at risk – those with Type I diabetes and those with Type II diabetes. The longer a person has diabetes, the higher their risk of developing some ocular problem. Between 40 to 45 percent of Americans diagnosed with diabetes have some stage of diabetic retinopathy. After 20 years of diabetes, nearly all patients with Type I diabetes and >60% of patients with Type II diabetes have some degree of retinopathy; however, these statistics were published in 2002 using data from four years earlier, limiting the usefulness of the research. The subjects would have been diagnosed with diabetes in the late 1970s, before modern fast acting insulin and home glucose testing.
However, it has been shown that the widely accepted WHO and American Diabetes Association diagnostic cutoff for diabetes of a fasting plasma glucose ≥ 7.0 mmol/l (126 mg/dl) does not accurately identify diabetic retinopathy among patients. The cohort study included a multi-ethnic, cross-sectional adult population sample in the US, as well as two cross-sectional adult populations in Australia. For the US-based component of the study, the sensitivity was 34.7% and specificity was 86.6%. For patients at similar risk to those in this study (15.8% had diabetic retinopathy), this leads to a positive predictive value of 32.7% and negative predictive value of 87.6%.
During pregnancy, diabetic retinopathy may also be a problem for women with diabetes. It is recommended that all pregnant women with diabetes have dilated eye examinations each trimester to protect their vision.
People with Down's syndrome, who have extra chromosome 21 material, almost never acquire diabetic retinopathy. This protection appears to be due to the elevated levels of endostatin, an anti-angiogenic protein, derived from collagen XVIII. The collagen XVIII gene is located on chromosome 21.
Diabetic retinopathy is the result of microvascular retinal changes. Hyperglycemia-induced intramural pericyte death and thickening of the basement membrane lead to incompetence of the vascular walls. These damages change the formation of the blood-retinal barrier and also make the retinal blood vessels become more permeable. Hypoxia has been implicated as a causative factor in the degradation of the retina and some early investigations have supported this hypothesis.
The pericyte death is caused when "hyperglycemia persistently activates protein kinase C-δ (PKC-δ, encoded by Prkcd) and p38 mitogen-activated protein kinase (MAPK) to increase the expression of a previously unknown target of PKC-δ signaling, Src homology-2 domain–containing phosphatase-1 (SHP-1), a protein tyrosine phosphatase. This signaling cascade leads to PDGF receptor- dephosphorylation and a reduction in downstream signaling from this receptor, resulting in pericyte apoptosis…"
Small blood vessels – such as those in the eye – are especially vulnerable to poor blood sugar (blood glucose) control. An overaccumulation of glucose and/or fructose damages the tiny blood vessels in the retina. During the initial stage, called nonproliferative diabetic retinopathy (NPDR), most people do not notice any change in their vision. Early changes that are reversible and do not threaten central vision are sometimes termed simplex retinopathy or background retinopathy.
Some people develop a condition called macular edema. It occurs when the damaged blood vessels leak fluid and lipids onto the macula, the part of the retina that lets us see detail. The fluid makes the macula swell, which blurs vision.
Proliferative diabetic retinopathy
As the disease progresses, severe nonproliferative diabetic retinopathy enters an advanced, or proliferative (PDR), stage when blood vessels proliferate (i.e. grow). The lack of oxygen in the retina causes fragile, new, blood vessels to grow along the retina and in the clear, gel-like vitreous humour that fills the inside of the eye. Without timely treatment, these new blood vessels can bleed, cloud vision, and destroy the retina. Fibrovascular proliferation can also cause tractional retinal detachment. The new blood vessels can also grow into the angle of the anterior chamber of the eye and cause neovascular glaucoma.
Nonproliferative diabetic retinopathy shows up as cotton wool spots, or microvascular abnormalities or as superficial retinal hemorrhages. Even so, the advanced proliferative diabetic retinopathy (PDR) can remain asymptomatic for a very long time, and so should be monitored closely with regular checkups.
Diabetic retinopathy is detected during an eye examination that includes:
- Visual acuity test: This test uses an eye chart to measure how well a person sees at various distances (i.e., visual acuity).
- Pupil dilation: The eye care professional places drops into the eye to dilate the pupil. This allows him or her to see more of the retina and look for signs of diabetic retinopathy. After the examination, close-up vision may remain blurred for several hours.
- Ophthalmoscopy or fundus photography: Ophthalmoscopy is an examination of the retina in which the eye care professional: (1) looks through a slit lamp biomicroscope with a special magnifying lens that provides a narrow view of the retina, or (2) wearing a headset (indirect ophthalmoscope) with a bright light, looks through a special magnifying glass and gains a wide view of the retina. Hand-held ophthalmoscopy is insufficient to rule out significant and treatable diabetic retinopathy. Fundus photography generally recreate considerably larger areas of the fundus, and has the advantage of photo documentation for future reference, as well as availing the image to be examined by a specialist at another location and/or time.
- Fundus Fluorescein angiography (FFA): This is an imaging technique which relies on the circulation of Fluorescein dye to show staining, leakage, or non-perfusion of the retinal and choroidal vasculature.
- Optical coherence tomography (OCT): This is an optical imaging modality based upon interference, and analogous to ultrasound. It produces cross-sectional images of the retina (B-scans) which can be used to measure the thickness of the retina and to resolve its major layers, allowing the observation of swelling.
- Digital Retinal Screening Programs: Systematic programs for the early detection of eye disease including diabetic retinopathy are becoming more common, such as in the UK, where all people with diabetes are offered retinal screening at least annually. This involves digital image capture and transmission of the images to a digital reading center for evaluation and treatment referral. See Vanderbilt Ophthalmic Imaging Center and the NHS Diabetic Eye Screening Programme The name Diabetic Retinopathy Screening Service (DRSS) is also used.
- Computer Vision Approach: It is a System developed by Researchers at IIT Kharagpur in collaboration with IBM India. It uses data analytics capabilities to automatically compare and analyse retina images of the patient. It can tell if the patient has DR and also provides risk categorisation ranging from low to medium and high.
- Slit Lamp Biomicroscopy Retinal Screening Programs: Systematic programs for the early detection of diabetic retinopathy using slit-lamp biomicroscopy. These exist either as a standalone scheme or as part of the Digital program (above) where the digital photograph was considered to lack enough clarity for detection and/or diagnosis of any retinal abnormality.
The eye care professional will look at the retina for early signs of the disease, such as:
- leaking blood vessels,
- retinal swelling, such as macular edema,
- pale, fatty deposits on the retina (exudates) – signs of leaking blood vessels,
- damaged nerve tissue (neuropathy), and
- any changes in the blood vessels.
If macular edema is suspected, FFA and sometimes OCT may be performed.
According to a DRSS user manual, poor quality images (which may apply to other methods) may be caused by cataract, poor dilation, ptosis, external ocular condition, or learning difficulties. There may be artefacts caused by dust, dirt, condensation, or smudge.
There are three major treatments for diabetic retinopathy, which are very effective in reducing vision loss from this disease. In fact, even people with advanced retinopathy have a 90 percent chance of keeping their vision when they get treatment before the retina is severely damaged. These three treatments are laser surgery, injection of corticosteroids or anti-VEGF agents into the eye, and vitrectomy.
Although these treatments are very successful (in slowing or stopping further vision loss), they do not cure diabetic retinopathy. Caution should be exercised in treatment with laser surgery since it causes a loss of retinal tissue. It is often more prudent to inject triamcinolone or anti-VEGF drugs. In some patients it results in a marked increase of vision, especially if there is an edema of the macula.
Avoiding tobacco use and correction of associated hypertension are important therapeutic measures in the management of diabetic retinopathy.
Laser photocoagulation can be used in two scenarios for the treatment of diabetic retinopathy. It can be used to treat macular edema by creating a Modified Grid at the posterior pole and it can be used for panretinal coagulation for controlling neovascularization. It is widely used for early stages of proliferative retinopathy.
Modified Grid Laser photocoagulation
A 'C' shaped area around the macula is treated with low intensity small burns. This helps in clearing the macular edema.
Panretinal photocoagulation, or PRP (also called scatter laser treatment), is used to treat proliferative diabetic retinopathy (PDR). The goal is to create 1,600 - 2,000 burns in the retina with the hope of reducing the retina's oxygen demand, and hence the possibility of ischemia. It is done in multiple sittings.
In treating advanced diabetic retinopathy, the burns are used to destroy the abnormal blood vessels that form in the retina. This has been shown to reduce the risk of severe vision loss for eyes at risk by 50%.
Before using the laser, the ophthalmologist dilates the pupil and applies anaesthetic drops to numb the eye. In some cases, the doctor also may numb the area behind the eye to reduce discomfort. The patient sits facing the laser machine while the doctor holds a special lens on the eye. The physician can use a single spot laser or a pattern scan laser for two dimensional patterns such as squares, rings and arcs. During the procedure, the patient will see flashes of light. These flashes often create an uncomfortable stinging sensation for the patient. After the laser treatment, patients should be advised not to drive for a few hours while the pupils are still dilated. Vision will most likely remain blurry for the rest of the day. Though there should not be much pain in the eye itself, an ice-cream headache like pain may last for hours afterwards.
Patients will lose some of their peripheral vision after this surgery although it may be barely noticeable by the patient. The procedure does however save the center of the patient's sight. Laser surgery may also slightly reduce colour and night vision.
A person with proliferative retinopathy will always be at risk for new bleeding, as well as glaucoma, a complication from the new blood vessels. This means that multiple treatments may be required to protect vision.
Intravitreal triamcinolone acetonide
Triamcinolone is a long acting steroid preparation. When injected in the vitreous cavity, it decreases the macular edema (thickening of the retina at the macula) caused due to diabetic maculopathy, and results in an increase in visual acuity. The effect of triamcinolone is transient, lasting up to three months, which necessitates repeated injections for maintaining the beneficial effect. Best results of intravitreal Triamcinolone have been found in eyes that have already undergone cataract surgery. Complications of intravitreal injection of triamcinolone include cataract, steroid-induced glaucoma and endophthalmitis.
Intravitreal anti-VEGF drugs
There are good results from multiple doses of intravitreal injections of anti-VEGF drugs such as bevacizumab. Present recommended treatment for diabetic macular edema is Modified Grid laser photocoagulation combined with multiple injections of anti-VEGF drugs.
Instead of laser surgery, some people require a vitrectomy to restore vision. A vitrectomy is performed when there is a lot of blood in the vitreous. It involves removing the cloudy vitreous and replacing it with a saline solution.
Studies show that people who have a vitrectomy soon after a large hemorrhage are more likely to protect their vision than someone who waits to have the operation. Early vitrectomy is especially effective in people with insulin-dependent diabetes, who may be at greater risk of blindness from a hemorrhage into the eye.
Vitrectomy is often done under local anesthesia. The doctor makes a tiny incision in the sclera, or white of the eye. Next, a small instrument is placed into the eye to remove the vitreous and insert the saline solution into the eye.
Patients may be able to return home soon after the vitrectomy, or may be asked to stay in the hospital overnight. After the operation, the eye will be red and sensitive, and patients usually need to wear an eyepatch for a few days or weeks to protect the eye. Medicated eye drops are also prescribed to protect against infection.
Vitrectomy is frequently combined with other modalities of treatment.
Light mask treatment is designed to be worn at night, to deliver a precise dose of light therapy during a patient’s normal hours of sleep. It comes in two parts – a plastic “Pod” part, which is inserted into a soft cushioned Fabric Mask. The Pod contains the light sources which, when worn, emit light into the eyes through closed eyelids. Nothing is inserted into the eyes – the treatment is non-invasive. The mask is programmed to administer the correct dose of light each night as part of a continuing therapy.
The colour of the light has been specifically chosen as the most effective for the treatment of Diabetic Retinopathy. The light may initially appear bright when the mask is first worn, but the eyes adjust within a few minutes as the brain learns to ignore the light, by what is known as the Troxler effect. The light from the mask stops the retina from dark adapting, which is thought to affect Diabetic Retinopathy.
How does it work?
In the human eye an image is projected through the lens to the retina at the back of the eye. There are two sorts of cells in the retina that detect the light (the image) and send a signal to the brain. These cells are called rods and cones. The cones work well during the day when there is a lot of light, but at night time the rods, which are more sensitive to low light levels, take over and dark adapt.
As the rods dark adapt they require more oxygen. In a healthy eye there is just enough oxygen to cope with demand, but in a diabetic person’s eye where circulation is compromised, the retina becomes starved of oxygen, a condition known as hypoxia. The body responds by producing a chemical known as VEGF (Vascular Endothelial Growth Factor) that results in the growth of new blood vessels in the eye to supply extra oxygen. In the diabetic eye these new vessels are weak, which makes the retina thicker. The build-up of fluid is termed Oedema and further reduces the amount of oxygen available, creating a vicious cycle. If the new blood vessels reach the macula (central part of the eye) and there is a build-up of fluid, then a patient’s eyesight, particularly their central vision, is affected. This is known as Macular Oedema.
Light treatment combats this cycle by illuminating the eye overnight through closed eyelids. The colour of the light is specially chosen to be absorbed primarily by the rods without affecting the cones (which would keep people awake), and the brightness is tuned to ensure that the rods do not dark adapt. As the rods do not dark adapt, their oxygen requirements remain at low daytime levels. The effect of this is to slow or stop the production of VEGF, avoid the formation of weak new blood vessels, avoid fluid leakage and oedema and allow the retina to repair itself to the best of its ability.
Though not yet commercially available, c-peptide has shown promising results in treatment of diabetic complications incidental to vascular degeneration. Once thought to be a useless byproduct of insulin production, it helps to ameliorate and reverse many symptoms of diabetes.
Stem cell therapy
Clinical trials are under way or are being populated in preparation for study at medical centers in Brazil, Iran and the United States. Current trials involve using the patients own stem cells derived from bone marrow and injected into the degenerated areas in an effort to regenerate the vascular system.
- Diabetic diet
- Purtscher's retinopathy, a disease with similar abnormalities in the eye, usually caused by trauma.
- Retinal regeneration
- "Diabetic retinopathy". Diabetes.co.uk. Retrieved 25 November 2012.
- Kertes PJ, Johnson TM, ed. (2007). Evidence Based Eye Care. Philadelphia, PA: Lippincott Williams & Wilkins. ISBN 0-7817-6964-7.[page needed]
- Tapp RJ; Shaw JE; Harper CA; et al. (June 2003). "The prevalence of and factors associated with diabetic retinopathy in the Australian population". Diabetes Care 26 (6): 1731–7. doi:10.2337/diacare.26.6.1731 (inactive 2015-01-12). PMID 12766102.
- Dr Caroline MacEwen. "diabetic retinopathy". Retrieved August 2, 2011.
- Engelgau, Michael, Linda Geiss, Jinan Saaddine, Jame Boyle, Stephanie Benjamin, Edward Gregg, Edward Tierney, Nilka Rios-Burrows, Ali Mokdad, Earl Ford, Giuseppina Imperatore, K. M. Venkat Narayan. "The Evolving Diabetes Burden in the United States." Annals of Internal Medicine, 1 June 2004. Web. 22 Apr. 2014.
- "Nonproliferative Diabetic Retinopathy (Includes Macular Edema)". Retrieved August 17, 2013.
- "Causes and Risk Factors". Diabetic Retinopathy. United States National Library of Medicine. 15 September 2009.
- Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (January 2003). "Report of the expert committee on the diagnosis and classification of diabetes mellitus". Diabetes Care 26 (Suppl 1): S5–20. doi:10.2337/diacare.26.2007.S5. PMID 12502614.
- The Expert Committee On The Diagnosis And Classification Of Diabetes Mellitus; James R. Gavin III, MD, PhD (Chair), Howard Hughes Medical Center, Bethesda, MD; K.G.M.M. Alberti, MD, University of Newcastle, Newcastle, U.K.; Mayer B. Davidson, MD, University of California, Los Angeles, CA; Ralph A. DeFronzo, MD, University of Texas, San Antonio, TX; Allan Drash, MD, University of Pittsburgh, Pittsburgh, PA; Steven G. Gabbe, MD, University of Washington, Seattle, WA; Saul Genuth, MD, Case West- ern Reserve University, Cleveland, OH; Maureen I. Harris, PhD, MPH, National Institutes of Health, Bethesda, MD; Richard Kahn, PhD, American Diabetes Associa- tion, Alexandria, VA; Harry Keen, MD, FRCP Guys Hospital, London, U.K.; William C. Knowler, MD, DrPH, National Institutes of Health, Phoenix, AZ; Harold Lebovitz, MD, State University of New York, Brooklyn, NY; Noel K. Maclaren, MD, University of Florida, Gainesville, FL; Jerry R Palmer, MD, University of Wash- ington, Seattle, WA; Philip Raskin, MD, University of Texas, Dallas, TX; Robert A. Rizza, MD, Mayo Clinic, Rochester, MN; Michael R Stern, MD, University of Texas, San Antonio, TX. (July 1997). "Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus" (PDF). Diabetes Care 20 (7): 1183–1197. doi:10.2337/diacare.20.7.1183 (inactive 2015-01-12). PMID 9203460. Retrieved Nov 23, 2013.
- Wong TY; Liew G; Tapp RJ; et al. (March 2008). "Lancet Revision, D-07-06757 The Relationship of Fasting Glucose to Retinopathy: Re-visiting a Key Criterion Used to Diagnose Diabetes". Lancet 371 (9614): 736–43. doi:10.1016/S0140-6736(08)60343-8. PMC 2350208. PMID 18313502.
- Williams R, Airey M, Baxter H, Forrester J, Kennedy-Martin T, Girach A; Airey; Baxter; Forrester; Kennedy-Martin; Girach (October 2004). "Epidemiology of diabetic retinopathy and macular oedema: a systematic review". Eye 18 (10): 963–83. doi:10.1038/sj.eye.6701476. PMID 15232600.
- Ryeom, Sandra; Folkman, Judah (2009). "Role of Endogenous Angiogenesis Inhibitors in Down Syndrome". Journal of Craniofacial Surgery 20 (Suppl 1): 595–6. doi:10.1097/SCS.0b013e3181927f47. PMID 19795527.
- Pardianto G; et al. (2005). "Understanding diabetic retinopathy". Mimbar Ilmiah Oftalmologi Indonesia 2: 65–6.
- Arden, G. B.; Wolf, J. E.; Tsang, Y. (1998-06). "Does dark adaptation exacerbate diabetic retinopathy?: Evidence and a linking hypothesis". Vision Research (11): 1723–11729. Check date values in:
- Arden, G. B.; Jyothi, S.; Hogg, C. H.; Lee, Y. F.; Sivaprasad, S. (2011-12-01). "Regression of early diabetic macular oedema is associated with prevention of dark adaptation". Eye 25 (12): 1546–1554. doi:10.1038/eye.2011.264. ISSN 0950-222X. PMC 3234487. PMID 22020171.
- Geraldes, Pedro; Hiraoka-Yamamoto, Junko; Matsumoto, Motonobu; Clermont, Allen; Leitges, Michael; Marette, Andre; Aiello, Lloyd P; Kern, Timothy S; King, George L (2009). "Activation of PKC-δ and SHP-1 by hyperglycemia causes vascular cell apoptosis and diabetic retinopathy". Nature Medicine 15 (11): 1298–306. doi:10.1038/nm.2052. PMC 3290906. PMID 19881493.
- Toke, Bek; Hammes, H-P; Porta, M. (eds) (2010). "Experimental Approaches to Diabetic Retinopathy - Front Diabetes". Clinical Presentations and Pathological Correlates of Retinopathy (PDF). Karger.com 20 (Basel). pp. 1–19.
- VUMC Web Development Team. "VanderbiltHealth.com : For Patients - General Information". retinopathyscreening.org.
- "NHS Diabetic Eye Screening Programme Home Page". screening.nhs.uk.
- Central Mersey Diabetic Retinopathy Screening Programme (NHS England), DRSS User Manual , 2009
- IANS (28 November 2012). "IIT Kharagpur pioneers Software for Fast Diagnosis of Diabetic Retinopathy". Biharprabha News.
- Masharani, Umesh (2006). "Diabetes Ocular complications". Chronic Complications of Diabetes. Armenian Medical Network.
- Fraser-Bell S, Kaines A, Hykin PG; Kaines; Hykin (May 2008). "Update on treatments for diabetic macular edema". Current Opinion in Ophthalmology 19 (3): 185–9. doi:10.1097/ICU.0b013e3282fb7c45. PMID 18408491.
- O'Malley, PG (Jul 9, 2012). "Comparative effectiveness of anti-growth factor therapies for diabetic macular edema: summary of primary findings and conclusions". Archives of internal medicine 172 (13): 1014–5. doi:10.1001/archinternmed.2012.2335. PMID 22688778.
- "Noctura 400 Sleep Mask for diabetic retinopathy ‐ Horizon Scanning Research & Intelligence Centre". www.hsric.nihr.ac.uk. Retrieved 2015-09-24.
- Wahren J, Ekberg K, Jörnvall H; Ekberg; Jörnvall (March 2007). "C-peptide is a bioactive peptide". Diabetologia 50 (3): 503–9. doi:10.1007/s00125-006-0559-y. PMID 17235526.
- Ljubimov, Alexander. "Stem Cell Therapy for Diabetic Retinopathy" (PDF). Cedars-Sinai Medical Center, Regenerative Medicine Institute, Los Angeles, CA, USA Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
- Grossman, Samuel. "A New Treatment for Diabetic Retinopathy". Diabetescare.net. Diabetescare.net. Retrieved 19 March 2015.
- The original text of this document was taken from the public domain resource document "Facts About Diabetic Retinopathy", at nei.nih.gov See the copyright statement at http://www.nei.nih.gov/order/index.htm, which says "Our publications are not copyrighted and may be reproduced without permission. However, we do ask that credit be given to the National Eye Institute, National Institutes of Health."
|Wikimedia Commons has media related to Diabetic retinopathy.|
- Diabetic Retinopathy Resource Guide from the National Eye Institute (NEI).
- National Diabetes Information Clearinghouse
- NHS Diabetic Eye Screening Programme